Oric Pharmaceuticals, Inc. (ORIC) Earnings
Oric Pharmaceuticals, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 3, 2026
From the latest earnings 8-K
Revenue • FY2025
$0
As reported
Diluted EPS • FY2025
-$1.47
▲ 19.7%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from ORIC's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$129.47M | — | -$1.47 | -$111.68M | — | — |
| FY2024 | $0 | -$127.85M | — | -$1.83 | -$113.85M | — | — |
| FY2023 | $0 | -$100.7M | — | -$1.96 | -$86.54M | — | — |
| FY2022 | $0 | -$89.12M | — | -$2.25 | -$77.22M | — | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 3, 2026 | 8-K (2.02) | 0001193125-26-330568EDGAR |
| May 4, 2026 | 8-K (2.02) | 0001193125-26-203993EDGAR |
| Feb 23, 2026 | 8-K (2.02) | 0001193125-26-063974EDGAR |
| Nov 13, 2025 | 8-K (2.02) | 0001193125-25-280196EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0000950170-25-107313EDGAR |
| May 5, 2025 | 8-K (2.02) | 0000950170-25-063540EDGAR |
| Feb 18, 2025 | 8-K (2.02) | 0000950170-25-022219EDGAR |
| Nov 12, 2024 | 8-K (2.02) | 0000950170-24-125386EDGAR |
Never miss a ORIC filing.
Get an email when ORIC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.